Tuesday, October 13, 2026

economic-policy

2 articles

Fiscal Constraints Limit Global Response as Geopolitical Shocks Threaten Inflation Revival

Fiscal Constraints Limit Global Response as Geopolitical Shocks Threaten Inflation Revival

UK Chancellor Rachel Reeves delivers a minimal spring statement this week, preserving fiscal capacity as government debt limits policy options across developed economies. The Iran conflict has pushed energy prices higher while debt trajectories force difficult trade-offs between economic support and fiscal credibility from Washington to London.

ViaNews Editorial Team•
US Debt to Surge $5.5 Trillion by 2034 as Social Security Faces 2032 Insolvency

US Debt to Surge $5.5 Trillion by 2034 as Social Security Faces 2032 Insolvency

The US will add $5.5 trillion to national debt by 2034 while Social Security bankruptcy threatens 24% benefit cuts by 2032. The fiscal crisis comes as the world's largest economy faces Fed leadership transition and entitlement program collapse, creating what Goldman Sachs calls a "reckoning" for global markets.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com